Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Wet AMD Clinical Trial

Official title:
Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

Status Active, not recruiting

Clinical Trial Summary

To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01310686
Study type	Observational
Source	West Coast Retina Medical Group, Inc.
Contact
Status	Active, not recruiting
Phase
Start date	April 2011
Completion date	June 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01016873` - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Phase 2
Withdrawn	`NCT01339949` - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)	N/A
Completed	`NCT00804934` - Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis	Phase 2
Recruiting	`NCT04704921` - Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD	Phase 2/Phase 3
Enrolling by invitation	`NCT05210803` - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting	`NCT00403026` - Intravitreal Bevacizumab for Retinal Disorders	N/A